Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Actelion spins out new firm as part of its acquisition by J&J; later named Idorsia, includes assets of Actelion's Vaxxilon division

Executive Summary

As part of its $30bn cash acquisition by Johnson & Johnson, Actelion Ltd. is spinning out its drug discovery operations and early-stage clinical assets into a new Swiss biopharma company (R&D NewCo).

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Acquisition
    • Divestiture/Spin-Out
    • Full Acquisition
    • Includes Earnout

Related Companies